Shimadzu presents the CLAM-2030

Shimadzu’s next-generation Clinical Laboratory Automation Module fully automates processes from pretreatment to biological LCMS analysis
| 3 min read
Register for free to listen to this article
Listen with Speechify
0:00
3:00
COLUMBIA, Md.—Shimadzu Scientific Instruments (SSI), the American subsidiary of Shimadzu Corp., has announced the release of the Clinical Laboratory Automation Module (CLAM-2030), a fully integrated sample pretreatment module for LCMS biological analysis. This innovation in automation is said to improve laboratory efficiency, enable fast and precise results, and maintain low operating costs.
Continue reading below...
A black mosquito is shown on pink human skin against a blurred green backdrop.
InfographicsDiscovering deeper insights into malaria research
Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Read More
By automating operations such as dispensing, stirring, filtering, heating and sample transfer, the system reportedly improves data accuracy and achieves the reproducibility needed for clinical research and forensic toxicology. Steps can be combined to perform tasks such as deproteination, internal standard addition, derivatization and glucuronidase digestion.
The CLAM-2030 facilitates users to reproducibly prepare samples and operate an LCMS, regardless of their skill level. With a streamlined workflow that interfaces with the laboratory information system (LIS), users can create and run sample batches with minimal effort. The STAT or Emergency Sample functionality allows users to prioritize urgent samples for quick results, with minimal interruption.
According to Shimadzu’s website, the CLAM-2030 fully automates processes from pretreatment to LCMS analysis; reduces variability in internal standard substance concentration, using vials with septa installed; is equipped with improved and expanded accuracy control functionality; and automates processes from searching toxicological drug libraries to generating reports. Automation also means that samples can be analyzed automatically, either at night or on days off.
Continue reading below...
A white, pink, and blue 3D molecular structure of a simple sugar is shown against a light purple background.
WebinarsAdding a little sugar: what glycomics can bring to medicine
Discover how glycoscience is transforming how scientists understand diseases and opening new doors for drug discovery.
Read More
The system also offers a variety of functions that elevate research and business efficiency, as it automates processes including searching toxicological drug libraries, providing the optimal analytical method, facilitating data review and generating reports. The CLAM-2030 can measure hundreds of compounds in a single analysis; the system makes it easy to change between different methods. Its flexible HPLC and MS configuration allows the unit to meet specific application needs.
Dedicated control software can enable analysis using SSI’s Triple Quad LCMS-8060/8050/8045/8040 systems. Optional LC/MS/MS rapid toxicology screening software includes methods for simultaneously or individually analyzing 161 components — including abused drugs, psychiatric and neurological drugs, hypnotics and sedatives, pharmaceuticals, pesticides and natural toxins.
Through automation, the CLAM-2030 can help to facilitate a safe working environment for laboratory personnel by minimizing human contact with potentially hazardous biological samples. Following pretreatment, solid and liquid waste are contained within the body of the CLAM-2030 and collected. The CLAM-20300 is intended for research use only, and is not for use in diagnostic procedures.
Continue reading below...
An illustration of various colored microbes, including bacteria and viruses
WebinarsCombatting multidrug-resistant bacterial infections
Organic molecules with novel biological properties offer new ways to eliminate multidrug-resistant bacteria.
Read More
Shimadzu Corp. also recently announced the release of the Nexera Ultra High-Performance Liquid Chromatograph series, which incorporates artificial intelligence as Analytical Intelligence, allowing systems to detect and resolve issues automatically. The Nexera series integrates IoT and device networking, enabling users to easily review instrument status, optimize resource allocation and achieve higher throughput.
The Nexera UHPLC series is said to maximize reliability and uptime with fully unattended workflows that span from startup to shut-down. Operators can set the Nexera to start up at a pre-specified time, so that it can complete auto-purge, equilibration, baseline checks and system suitability in advance, and be ready for analysis before researchers arrive at the lab. The Nexera also has auto-diagnostics and auto-recovery capabilities that allow it to monitor pressure fluctuations to check for anomalies. Nexera tracks consumable usage and sends alerts when parts need replacing, allowing users to keep the system running at peak performance.
Continue reading below...
A syringe with a needle drawing the vaccine out of a vial with ampules in the background
InfographicsTurbocharging mRNA vaccine development
Cell-free gene synthesis technology offers a quick, reliable route to creating vital mRNA vaccines and therapeutics.
Read More
Real-time monitoring of mobile phase levels can allow lab personnel to run batches and respond accordingly if there isn’t enough mobile phase before starting a run. The Nexera automatically blends mobile phases at any set ratio, which speeds up the preparation of buffer solutions and the dilution of solvents. Because it prepares the exact amounts required for analysis, the Nexera can reduce waste and labor. The Nexera UHPLC series also allows analysts to confirm parameters and monitor chromatograms in real time directly from a web browser on their smart device.

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Fluorescent-style illustration of spherical embryonic stem cells clustered together against a dark background.
Explore how emerging in vitro systems — built from primary cells, cocultures, and vascularized tissues — are improving translational research outcomes. 
3D illustration of ciliated cells, with cilia shown in blue.
Ultraprecise proteomic analysis reveals new insights into the molecular machinery of cilia.
3D illustration showing a DNA double helix encapsulated in a transparent capsule, surrounded by abstract white and orange protein-like molecular structures against a blue background.
Discover an integrated analytical approach that unites identification, purification, and stability assessment for therapeutic molecules.
Drug Discovery News December 2025 Issue
Latest IssueVolume 21 • Issue 4 • December 2025

December 2025

December 2025 Issue

Explore this issue